HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update
PR Newswire Asia
· Delivered solid performance to start 2024, with record-breaking first quarter revenue of 34.1 billion KRW. Strong sales momentum..
· Delivered solid performance to start 2024, with record-breaking first quarter revenue of 34.1 billion KRW. Strong sales momentum..
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "VRDN-001 Market Size, Forecast, and Emerging Insight - 2032" report has been added..
ROCKVILLIE, Md. and SUZHOU, China, March 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a..